TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02385305

Intervention type: DEVICE
Group type: OTHER
Intervention: Pressure support ventilation by anesthesia machine (Apollo, Dräger)
Description: Pressure support ventilation will be applied by anesthesia machine (Apollo, Dräger) with pressure support (PS) of 3, 8, 13 and 18 cmH2O in this order, with slope of 1.0 second and no PEEP. The fraction of inspired oxygen will be titrated to achieve SpO2 over 98%. Five minutes will be allowed to achieve equilibrium at each PS level after which an additional recording of one minute of data will be obtained. Once the Pressure support ventilation is completed at 18 cmH2O, ventilation will be carried out in reverse order of PS; 13, 8 and 3 cmH2O of PS.
Study: NCT02869087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Akesys Prava Scaffold
Description: Implantation of the Akesys Prava Sirolimus Eluting Bioresorbable Peripheral Scaffold System
Study: NCT03927950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: escitalopram 10-20mg per day 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion
Description: bupropion 150-300mg per day 6 weeks
Study: NCT03443882

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthin
Description: an oral dose form

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthin
Description: an oral dose form

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthin
Description: an oral dose form

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin
Description: an oral dose form
Study: NCT04448171

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TENS
Description: Standard TENS unit with four pads affixed to the lower back area, will be used in this arm. The TENS device will be set to an active setting.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham TENS
Description: Standard TENS unit with four pads affixed to the lower back area, will be used in this arm. The TENS device will be set to an inactive setting.
Study: NCT04025385

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Training
Description: Training for 25 min with four 1 minute intervals when participants exercise up to 80% of their individual limits.
Study: NCT04654728

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Active Comparator: ePTFE graft
Description: In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: ePTFE graft
Description: In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
Study: NCT02967133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Arm A: Nivolumab 240 mg via intravenous infusion (IV) over 30 minutes day 1 of each 14 day cycle until disease progression or not tolerated.~Arm B: Nivolumab 360 mg via intravenous infusion (IV) over 30 minutes day 1 of every 21 day treatment cycle until progression or not tolerated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Arm A: Nivolumab 240 mg via intravenous infusion (IV) over 30 minutes day 1 of each 14 day cycle until disease progression or not tolerated.~Arm B: Nivolumab 360 mg via intravenous infusion (IV) over 30 minutes day 1 of every 21 day treatment cycle until progression or not tolerated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: Patients in arm B receive nab-paclitaxel at a dose of 100 mg/m2 over intravenous infusion on Days 1 and 8 of each 21 day cycle.
Study: NCT02976012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: . Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) \<21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: . Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) \<21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endolaserless Vitrectomy
Description: Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endolaserless Vitrectomy
Description: Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage
Study: NCT00701428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan 50 mg daily during 6 + 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan 50 mg daily during 6 + 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan 50 mg daily during 6 + 6 weeks
Study: NCT03945188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
Study: NCT04530448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care treatment
Study: NCT06410677

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA Sequencing, RNA Sequencing
Description: High-coverage Whole-Exome Sequencing sequencing of DNA samples from ESCC was performed.~RNA expression was analyzed using the NanoString PanCancer Immuno-Oncology 360TM Panel that includes a set of more than 700 genes involved in the main biological pathways of human immunity. These experiments were performed by the Genomics platform of Institut Curie. Total RNAs were used as templates.
Study: NCT00701428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP during the second 6 week-period
Study: NCT03760133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duolac
Description: Participants included in this group will be taken probiotics for 1 month after bowel preparation for colonoscopy.
Study: NCT00542516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl Starch
Description: Dosage: 30ml/kg; frequency: one time; duration: 60min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethyl Starch
Description: Dosage: 30ml/kg; frequency: one time; duration: 60min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: Dosage: 30ml/kg; frequency: one time; duration: 60min.After 10ml-kg-h both groups
Study: NCT04585555

Intervention type: DEVICE
Intervention: Accuryn Monitoring System
Description: The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
Study: NCT00310856

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: Subjects received the full dose (0.5 mL) of MenACWY-CRM, obtained by extemporaneous mixing of lyophilized MenA powder component and the MenCWY suspension, administered by IM injection into the anterolateral area of the right thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: Subjects received the full dose (0.5 mL) of MenACWY-CRM, obtained by extemporaneous mixing of lyophilized MenA powder component and the MenCWY suspension, administered by IM injection into the anterolateral area of the right thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: Subjects received the full dose (0.5 mL) of MenACWY-CRM, obtained by extemporaneous mixing of lyophilized MenA powder component and the MenCWY suspension, administered by IM injection into the anterolateral area of the right thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenC-CRM
Description: One dose (0.5 mL) of MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized MenC component and a saline solvent, administered by IM injection into the arm region.
Study: NCT01558557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten Free Diet
Description: Participants will be given a Gluten Free Diet for 2 weeks
Study: NCT05130541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proning
Description: Rotating on long axis 90 degrees every 30 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Care
Description: Usual Care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Usual Care
Study: NCT02454816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single HIV RDT and single syphilis RDT
Description: It is a diagnostic intervention, at the cluster level This arm includes a single (separate) rapid test for HIV and Syphilis. In this case pregnant women enrolled are sampled with two drops of blood (one for each cassette). Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual HIV/syphilis RDT
Description: It is a diagnostic intervention, at the cluster level. This arm includes a dual rapid test for HIV and syphilis, which means that in the same cassette will be available the information about the results for both conditions. In this case pregnant women enrolled are sampled with one drop for the cassette, which is enough to get both of the results. Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
Study: NCT00310856

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-Hib-IPV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-Hib-IPV
Study: NCT02445157

Intervention type: OTHER
Intervention: 4MGS
Description: Measurement of usual gait speed over 4 metres (metres/second)
Study: NCT00310856

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-Hib-IPV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PC7
Description: One dose (0.5 mL) of PC7, supplied in pre-filled syringe, administered by IM injection into the anterolateral area of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PC7
Description: One dose (0.5 mL) of PC7, supplied in pre-filled syringe, administered by IM injection into the anterolateral area of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PC7
Description: One dose (0.5 mL) of PC7, supplied in pre-filled syringe, administered by IM injection into the anterolateral area of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella
Study: NCT04661189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise training
Description: Participants will be encouraged to complete exercise training programs in the form of video capsules available via Facebook or Youtube, created by kinesiologists of the Montreal Heart Institut EPIC prevention center. The videos last about 15 minutes and include a warm-up of 3 to 5 minutes, followed a 10-minute training and finally a 2-minute cool-down period. The exercises on video do not require any equipment and integrate, depending on the video, aerobic, muscular strengthening, flexibility and/or balance exercises. Several intensities are described according to the participants' level. Participants will be invited to perform exercise sessions at least 5 times a week, and will be monitored weekly by phone by a member of the research team. The exercise sessions can be performed at home using the video training program, as well as in sports centre or outdoors. For each session, participants have to report its duration, intensity, and the nature of the activity via a follow-up agenda.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise training
Description: Participants will be encouraged to complete exercise training programs in the form of video capsules available via Facebook or Youtube, created by kinesiologists of the Montreal Heart Institut EPIC prevention center. The videos last about 15 minutes and include a warm-up of 3 to 5 minutes, followed a 10-minute training and finally a 2-minute cool-down period. The exercises on video do not require any equipment and integrate, depending on the video, aerobic, muscular strengthening, flexibility and/or balance exercises. Several intensities are described according to the participants' level. Participants will be invited to perform exercise sessions at least 5 times a week, and will be monitored weekly by phone by a member of the research team. The exercise sessions can be performed at home using the video training program, as well as in sports centre or outdoors. For each session, participants have to report its duration, intensity, and the nature of the activity via a follow-up agenda.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed different mnemotechnic, as well as be taught about memory in aging in general. The memory training will be provided by videos capsules. To track adherence to cognitive training, participants will be asked to complete a journal and mark days and times where they took part in the various cognitive training sessions.
Study: NCT02115945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DN4 test
Description: The DN4 test was used to evaluate neuropathic pain.
Study: NCT04341116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ003234
Description: patients receive a single infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ003234
Description: patients receive a single infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ003234
Description: patients receive a single infusion
Study: NCT00310856

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella
Study: NCT04341116

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients receive a single infusion
Study: NCT03928080

Intervention type: DIAGNOSTIC_TEST
Intervention: Bleeding on brushing
Description: Index tests are bleeding on brushing and aMMP-8 Gold standard: clinical diagnosis performed by specialist

Intervention type: DIAGNOSTIC_TEST
Intervention: Bleeding on brushing
Description: Index tests are bleeding on brushing and aMMP-8 Gold standard: clinical diagnosis performed by specialist
Study: NCT00627484

Intervention type: PROCEDURE
Intervention: Gastric bypass
Description: NOTE: the surgery is not paid for by the study

Intervention type: PROCEDURE
Intervention: Gastric bypass
Description: NOTE: the surgery is not paid for by the study

Intervention type: PROCEDURE
Intervention: Gastric banding
Description: NOTE: the surgery is not paid for by the study

Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy
Description: NOTE: the surgery is not paid for by the study

Intervention type: BEHAVIORAL
Intervention: Very low calorie diet
Description: Weight loss with calorie restricted liquid diet. Subject will be asked to stay in our in-patient research unit for 2-3 weeks and consume only those foods supplied by our bionutrition unit. Expected weight loss should be between 7-10% of body weight. Subjects will receive the diet at no cost and will be compensated for their time.
Study: NCT02246179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFXL
Description: Pretreatment at 2.5 mJ/microbeam and 5% density Pain stimulus at 35 mJ/microbeam and 5% density

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFXL
Description: Pretreatment at 2.5 mJ/microbeam and 5% density Pain stimulus at 35 mJ/microbeam and 5% density

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AFXL
Description: Pretreatment at 2.5 mJ/microbeam and 5% density Pain stimulus at 35 mJ/microbeam and 5% density

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AFXL
Description: Pretreatment at 2.5 mJ/microbeam and 5% density Pain stimulus at 35 mJ/microbeam and 5% density

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHES
Description: Topical application at test region 1 and 3 under occlusion for 10 minutes

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: AHES
Description: Topical application at test region 1 and 3 under occlusion for 10 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA cream
Description: Topical application at test region 2 and 4 under occlusion for 10 minutes

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: EMLA cream
Description: Topical application at test region 2 and 4 under occlusion for 10 minutes
Study: NCT01289860

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavonoids
Description: 475g of anthocyanidins in 300ml of blueberry drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 29g powder: sugars (glucose, sucrose, fructose), vitamin C and citric acid.
Study: NCT02739425

Intervention type: DEVICE
Group type: OTHER
Intervention: Sentimag Device
Description: The programme will compare the Sentimag with the conventional sentinel lymph node detection with radioactive tracer combined with blue dye (in centres using the combined technique) and thereby determine whether the new technique is equivalent to the standard technique for SLNB
Study: NCT03468686

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral rTMS
Description: The coil will locate on F3 and F4 in accordance with the 10-20 international system. bilateral rTMS include stimulate the right DLPFC at 1 Hz for a 10 seconds train of stimulation, and a total of 150 pulse trains. Immediately after that, the stimulation was carried out on the left DLPFC at 10 Hz, 5 seconds of stimulation, with 10 second inter-train interval and 75 pulse trains.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: The same parameters will use in the sham rTMS. However, the coil adjust at an angle of 90º vertically on the skull in a way that one wing place on the head.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral rTMS (High frequency)
Description: The coil will locate on F3 in accordance with the 10-20 international system. Unilateral rTMS include stimulate the Left DLPFC at 10Hz for a 5seconds train of stimulation, 10 seconds inter-train interval, and a total of 75 pulse trains. .
Study: NCT03691987

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Preprocessed thawed donor FMT
Description: Delivered as an enema using the same equipment and technique as X-ray of the colon

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Preprocessed thawed autologous FMT
Description: Delivered as an enema using the same equipment and technique as X-ray of the colon
Study: NCT01399775

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implantation
Description: Immediately after tooth extraction, a dental implant is inserted

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Delayed implantation
Description: Four months after extraction, a dental implant is inserted and measurements are recorded.
Study: NCT00936143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infliximab
Description: 100mg/bottle 5mg/kg inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
Study: NCT00410735

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pranlukast hydrate
Description: 225 mg BID for 12 weeks
Study: NCT03272295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference cigarette
Description: The reference product is based on a commercially-available king-size cigarette design (length 83 mm, circumference 24.6 mm) with a single segment cellulose acetate filter and tobacco blend recipe without ingredients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference cigarette
Description: The reference product is based on a commercially-available king-size cigarette design (length 83 mm, circumference 24.6 mm) with a single segment cellulose acetate filter and tobacco blend recipe without ingredients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with carob bean extract
Description: Based on reference cigarette with added ingredient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with cocoa powder
Description: Based on reference cigarette with added ingredient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with fenugreek extract
Description: Based on reference cigarette with added ingredient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with fig juice
Description: Based on reference cigarette with added ingredient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with glycerol
Description: Based on reference cigarette with added ingredient
Study: NCT04875481

Intervention type: OTHER
Intervention: Psychiatric diagnosis
Description: Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5

Intervention type: OTHER
Intervention: Psychiatric diagnosis
Description: Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5

Intervention type: OTHER
Intervention: ASD diagnosis
Description: Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)